EMA Authorised: Fulphila (pegfilgrastim) — Biosimilar Collaborations Ireland Limited

View source ↗

Summary

EMA authorised Fulphila, a pegfilgrastim biosimilar by Biosimilar Collaborations Ireland Limited. The approval covers its use to reduce the duration of neutrope…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Neutropenia
• Febrile Neutropenia
• Malignant Neoplasms
• Neutropenia

Drugs mentioned

• Fulphila (pegfilgrastim)

Snippet

Status: Authorised. MAH: Biosimilar Collaborations Ireland Limited. Decision date: 17/02/2026